ADAR1 Capital Management, LLC filed a Form 4 on November 9, 2026, disclosing two open-market purchases of NextCure, Inc. common stock totaling 4,686 shares made on November 5 and November 6, 2026.
Key Highlights
- Issuer: NextCure, Inc., trading on NASDAQ:NXTC
- Reporting persons: ADAR1 Capital Management, LLC and Daniel Schneeberger, sole manager, both identified as 10% owners
- First purchase: 1,024 shares acquired on November 5, 2026, at $5.1 per share
- Second purchase: 3,662 shares acquired on November 6, 2026, at $5.1 per share
- Resulting ownership: 737,956 shares of common stock beneficially owned indirectly following both transactions
- Ownership structure: Securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC
- Beneficial ownership disclaimer: Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest
ADAR1 Capital Management's Two-Day Purchase of NextCure Common Stock
According to the filing, ADAR1 Capital Management, LLC and Daniel Schneeberger jointly submitted a Form 4 covering two purchase transactions in NextCure, Inc. common stock. On November 5, 2026, the reporting persons acquired 1,024 shares at a price of $5.1 per share, bringing indirectly held beneficial ownership to 734,294 shares. The following day, November 6, 2026, an additional 3,662 shares were purchased at the same price of $5.1 per share, bringing total indirectly held beneficial ownership to 737,956 shares. Both transactions carried transaction code "P," indicating open-market purchases.
The filing states that the reported securities "are owned directly by private investment funds managed by ADAR1 Capital Management, LLC," and may be deemed indirectly beneficially owned by both ADAR1 Capital Management, LLC and Daniel Schneeberger in his capacity as the sole manager of the firm. All shares are reported as indirectly held. No derivative securities transactions were reported in Table II of the filing.
As noted in the filing's explanation of responses, each reporting person "disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any," and the report is stated not to constitute an admission of beneficial ownership for purposes of Section 16 or otherwise. The form was signed by Daniel Schneeberger on November 9, 2026.
What Was Disclosed
ADAR1 Capital Management, LLC and Daniel Schneeberger disclosed two purchases of NextCure, Inc. common stock totaling 4,686 shares at $5.1 per share on November 5 and 6, 2026, resulting in indirect beneficial ownership of 737,956 shares.




Please wait processing your request...